Plasma cell tumors in experimental chemotherapy: consequence of dose variation on host survival and paraprotein synthesis.
D000814:Aniline Compounds / Q000008:administration & dosage; D000818:Animals; D001796:Blood Protein Disorders / Q000139:chemically induced*; D001797:Blood Protein Electrophoresis; D001815:Bloodletting; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use*; D051379:Mice; D009368:Neoplasm Transplantation; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D010954:Plasmacytoma / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D012712:Serum Globulins / Q000096:biosynthesis*; D014508:Urea / Q000008:administration & dosage / Q000627:therapeutic use*
D000814:Aniline Compounds; D009588:Nitrogen Mustard Compounds; D012712:Serum Globulins; D003520:Cyclophosphamide; D014508:Urea; D005472:Fluorouracil